You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

metastatic BRAF V600 mutated melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Associated Factors, and Clinical Outcomes of Prescribing

Completed
  • BRAF v600 Mutated Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Pharmaceuticals
    Mar 28, 2023

    Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

    Recruiting
    • Clinical Stage IV Cutaneous Melanoma AJCC v8
    • +3 more
    • Scottsdale, Arizona
    • +2 more
    Jan 4, 2023

    BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

    Completed
    • BRAF V600E Unresectable or Metastatic Melanoma
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Jun 9, 2022

    Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)

    Terminated
    Has Results
    • Malignant Melanoma
    • Brain Metastases
    • Tucson, Arizona
      University of Arizona Cancer Center
    Mar 5, 2022

    Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

    Active, not recruiting
    • Melanoma
    • Boston, Massachusetts
    • +2 more
    Jun 14, 2022

    Melanoma (Skin) Trial in Dijon, Thionville, Vandœuvre-lès-Nancy (Blood sampling)

    Active, not recruiting
    • Melanoma (Skin)
    • Blood sampling
    • Dijon, France
    • +3 more
    Mar 29, 2022

    Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

    Recruiting
    • Clinical Stage IV Cutaneous Melanoma AJCC v8
    • Metastatic Melanoma
    • Dabrafenib Mesylate
    • +2 more
    • Atlanta, Georgia
    • +6 more
    Nov 30, 2022

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

    Not yet recruiting
    • Non-small-cell Lung Cancer
    • (no location specified)
    Jun 8, 2023

    Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

    Recruiting
    • Melanoma (Skin)
    • +2 more
      • Evora, Portugal
        Hospital Evora
      May 30, 2022

      Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

      Recruiting
      • Metastatic Melanoma
      • BRAF Gene Mutation
      • Nilotinib 100mg
      • +5 more
      • Lexington, Kentucky
        Markey Cancer Center
      Jul 22, 2022

      Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

      Not yet recruiting
      • Colorectal Cancer
      • +4 more
      • (no location specified)
      Aug 18, 2022

      Melanoma, BRAF V600 Mutation, Unresectable Melanoma Trial in Rennes (Binimetinib Oral Tablet)

      Completed
      • Melanoma
      • +3 more
      • Binimetinib Oral Tablet
      • Rennes, France
        Biotrial
      Mar 31, 2023

      BRAF V600-mutated Lung Carcinoma Treated With Combination of

      Completed
      • Non Small Cell Lung Cancer
      • BRAF V600 Mutation
        • Créteil, France
        • +1 more
        Jun 29, 2022

        Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago

        Recruiting
        • Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
        • +2 more
        • Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
        • Chicago, Illinois
          Northwestern University
        Nov 16, 2022

        BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

        Active, not recruiting
        • BRAF V600E Mutation Present
        • +9 more
        • Boston, Massachusetts
        • +1 more
        Jun 28, 2022

        Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

        Not yet recruiting
        • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
        • Non-investigational
        • (no location specified)
        May 11, 2023

        Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)

        Active, not recruiting
        • Tumor Skin
        • +2 more
        • OBX-115
        • Orlando, Florida
        • +1 more
        Sep 28, 2023

        Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in BRAF Mutated

        Recruiting
        • Metastatic Melanoma
          • Montpellier, France
            Uhmontpellier
          Aug 19, 2022

          Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,

          Active, not recruiting
          • Metastatic Malignant Neoplasm in the Brain
          • +7 more
          • Houston, Texas
            M D Anderson Cancer Center
          Jun 15, 2022

          BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

          Recruiting
          • BRAF NP_004324.2:p.V600E
          • +2 more
          • Duarte, California
          • +1 more
          Jan 19, 2023

          V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma, Stage III or Stage IV Metastatic Melanoma That

          Terminated
          Has Results
          • V600-mutated BRAF Unresectable Melanoma
          • +2 more
          • Los Angeles, California
          • +5 more
          May 12, 2020

          Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)

          Recruiting
          • Colorectal Cancer
          • VIC
          • Bevacizumab Plus Chemotherapy
          • Shanghai, China
            Department of General Surgery, Zhongshan Hospital, Fudan Univers
          Sep 14, 2022

          Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)

          Not yet recruiting
          • Malignant Melanoma
          • +4 more
          • (no location specified)
          Mar 31, 2022

          Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

          Not yet recruiting
          • Cancer
          • +5 more
          • (no location specified)
          Aug 18, 2022